Rodney F. Pommier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rodney F. Pommier has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
SuEllen J. Pommier
Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA
12 shared publications- John T. Vetto
Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA
5 shared publications Kristine Calhoun
Division of Surgical Oncology, Department of General Surgery Oregon Health & Science University 3181 SW Sam Jackson Park Road, L223A 97201 Oregon Portland USA
5 shared publications- Arpana M. Naik
Division of Surgical Oncology, Oregon Health & Science University, USA
4 shared publications Belinda H. McCully
Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific–Northwest, Western University of Health Sciences, Lebanon, USA
4 shared publicationsKristen E. Limbach
Department of Surgery, Oregon Health & Science University, United states
4 shared publications
Latest Publications
- 10 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117099
Outcomes of Peptide Receptor Radionuclide Therapy After Progression Following Hepatic Cytoreductive Operation for Neuroendocrine Tumors
- 10 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117099
Outcomes of Peptide Receptor Radionuclide Therapy After Progression Following Hepatic Cytoreductive Operation for Neuroendocrine Tumors
- Open Access
- 27 January 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (4) , 2253-2255
Invited Editorial Regarding “Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors”, by Howe et al.
- 27 January 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (4) , 2253-2255
Open AccessInvited Editorial Regarding “Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors”, by Howe et al.
- 6 June 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5130-5131
Letter to the Editor Concerning “Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis” by Ammann, Markus et al.
- 6 June 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5130-5131
Letter to the Editor Concerning “Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis” by Ammann, Markus et al.
- 1 February 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 231, 41-45
Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases
- 1 February 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 231, 41-45
Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases
- 16 January 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (5) , 2996-3002
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was
- 16 January 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (5) , 2996-3002
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was
- Open Access
- 4 November 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (1) , 12-14
Invited Editorial on Surgical Treatment of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: Pay Close Attention to the Pathology Report
- 4 November 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (1) , 12-14
Open AccessInvited Editorial on Surgical Treatment of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: Pay Close Attention to the Pathology Report
- Open Access
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of malignancies originating from neuroendocrine cells of the gastrointestinal tract, the incidence of which has been increasing for several decades. While there has been significant progress in the development of therapeutic options for patients with advanced or metastatic disease, these remain limited both in quantity and durability of benefit. This review examines the latest research elucidating the mechanisms of both up-front resistance and the eventual development of resistance to the primary systemic therapeutic options including somatostatin analogues, peptide receptor radionuclide therapy with lutetium Lu 177 dotatate, everolimus, sunitinib, and temozolomide-based chemotherapy. Further, potential strategies for overcoming these mechanisms of resistance are reviewed in addition to a comprehensive review of ongoing and planned clinical trials addressing this important challenge.
Open AccessTherapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of malignancies originating from neuroendocrine cells of the gastrointestinal tract, the incidence of which has been increasing for several decades. While there has been significant progress in the development of therapeutic options for patients with advanced or metastatic disease, these remain limited both in quantity and durability of benefit. This review examines the latest research elucidating the mechanisms of both up-front resistance and the eventual development of resistance to the primary systemic therapeutic options including somatostatin analogues, peptide receptor radionuclide therapy with lutetium Lu 177 dotatate, everolimus, sunitinib, and temozolomide-based chemotherapy. Further, potential strategies for overcoming these mechanisms of resistance are reviewed in addition to a comprehensive review of ongoing and planned clinical trials addressing this important challenge.
- 31 March 2022
- Published by Elsevier in The American Journal of Surgery
- Vol. 224 (2) , 665-669
The prevalence, operations, and outcomes of carcinoid heart disease
- 31 March 2022
- Published by Elsevier in The American Journal of Surgery
- Vol. 224 (2) , 665-669
The prevalence, operations, and outcomes of carcinoid heart disease
- Open Access
Similar Outcomes in Minimally Invasive versus Open Management of Primary Pancreatic Neuroendocrine Tumors: A Regional, Multi-Institutional Collaborative Analysis
In pancreatic neuroendocrine tumors (PNETs), the impact of minimally invasive (MI) versus open resection on outcomes remains poorly studied. We queried a multi-institutional pancreatic cancer registry for patients with resected non-metastatic PNET from 1996–2020. Recurrence-free (RFS), disease-specific survival (DSS), and operative complications were evaluated. Two hundred and eighty-two patients were identified. Operations were open in 139 (49%) and MI in 143 (51%). Pancreaticoduodenectomy was performed in 77 (27%, n = 23 MI), distal pancreatectomy in 184 (65%, n = 109 MI), enucleation in 13 (5%), and total pancreatectomy in eight (3%). Median follow-up was 50 months. Thirty-six recurrences and 13 deaths from recurrent disease yielded 5-year RFS and DSS of 85% and 95%, respectively. On multivariable analysis, grade 1 (HR 0.07, p < 0.001) and grade 2 (HR 0.20, p = 0.002) tumors were associated with improved RFS, while T3/T4 tumors were associated with worse RFS (OR 2.78, p = 0.04). MI resection was not associated with RFS (HR 0.53, p = 0.14). There was insufficient mortality to evaluate DSS with multivariable analysis. Of 159 patients with available NSQIP data, incisional surgical site infections (SSIs), organ space SSIs, Grade B/C pancreatic fistulas, reoperations, and need for percutaneous drainage did not differ by operative approach (all p > 0.2). Nodal harvest was similar for MI versus open distal pancreatectomies (p = 0.16) and pancreaticoduodenectomies (p = 0.28). Minimally invasive surgical management of PNETs is equivalent for oncologic and postoperative outcomes.
Open AccessSimilar Outcomes in Minimally Invasive versus Open Management of Primary Pancreatic Neuroendocrine Tumors: A Regional, Multi-Institutional Collaborative Analysis
In pancreatic neuroendocrine tumors (PNETs), the impact of minimally invasive (MI) versus open resection on outcomes remains poorly studied. We queried a multi-institutional pancreatic cancer registry for patients with resected non-metastatic PNET from 1996–2020. Recurrence-free (RFS), disease-specific survival (DSS), and operative complications were evaluated. Two hundred and eighty-two patients were identified. Operations were open in 139 (49%) and MI in 143 (51%). Pancreaticoduodenectomy was performed in 77 (27%, n = 23 MI), distal pancreatectomy in 184 (65%, n = 109 MI), enucleation in 13 (5%), and total pancreatectomy in eight (3%). Median follow-up was 50 months. Thirty-six recurrences and 13 deaths from recurrent disease yielded 5-year RFS and DSS of 85% and 95%, respectively. On multivariable analysis, grade 1 (HR 0.07, p < 0.001) and grade 2 (HR 0.20, p = 0.002) tumors were associated with improved RFS, while T3/T4 tumors were associated with worse RFS (OR 2.78, p = 0.04). MI resection was not associated with RFS (HR 0.53, p = 0.14). There was insufficient mortality to evaluate DSS with multivariable analysis. Of 159 patients with available NSQIP data, incisional surgical site infections (SSIs), organ space SSIs, Grade B/C pancreatic fistulas, reoperations, and need for percutaneous drainage did not differ by operative approach (all p > 0.2). Nodal harvest was similar for MI versus open distal pancreatectomies (p = 0.16) and pancreaticoduodenectomies (p = 0.28). Minimally invasive surgical management of PNETs is equivalent for oncologic and postoperative outcomes.